| |
Methylated genes
|
|---|
|
Parameter
|
Overall
|
CDH1
|
DAPK
|
RARB
|
HIC1
|
FHIT
|
RASSF1A
|
APC
|
CDKN2A
|
MGMT
|
BRCA1
|
|
Histology
| | | | | | | | | | | |
|
SCC (N = 77)
|
66
|
45
|
36
|
24
|
12
|
9
|
5
|
5
|
6
|
4
|
3
|
|
AC (N = 5)
|
5
|
0
|
1
|
0
|
3
|
0
|
1
|
4
|
1
|
0
|
2
|
|
Significance
|
P = 1.00
|
P = 0.02
|
P = 0.372
|
P = 0.315
|
P = 0.040
|
P = 1.00
|
P = 0.323
|
P = 0.0003
|
P = 0.367
|
P = 1.00
|
P = 0.028
|
|
Stage
| | | | | | | | | | | |
|
I (N = 17)
|
10
|
6
|
5
|
3
|
5
|
0
|
4
|
2
|
2
|
0
|
0
|
|
II (N = 19)
|
19
|
13
|
12
|
5
|
3
|
3
|
2
|
2
|
1
|
0
|
2
|
|
III-IV (N = 46)
|
42
|
16
|
20
|
16
|
7
|
6
|
0
|
5
|
4
|
4
|
3
|
|
Significance
|
P = 0.0005
|
P = 0.0005
|
P = 0.129
|
P = 0.394
|
P = 0.460
|
P = 0.279
|
P = 0.003
|
P = 1.00
|
P = 0.759
|
P = 0.395
|
P = 0.397
|
|
Size of tumor
| | | | | | | | | | | |
|
1–5 cm (N = 32)
|
28
|
20
|
13
|
10
|
8
|
3
|
4
|
4
|
1
|
0
|
1
|
|
≥ 6 cm (N = 38)
|
34
|
21
|
19
|
13
|
6
|
4
|
1
|
3
|
4
|
2
|
2
|
|
Significance
|
P = 1.000
|
P = 0.540
|
P = 0.433
|
P = 0.793
|
P = 0.337
|
P = 1.00
|
P = 0.171
|
P = 0.695
|
P = 0.366
|
P = 0.497
|
P = 1.000
|
|
Age (yrs)
| | | | | | | | | | | |
|
≤ 40 (N = 32)
|
28
|
17
|
17
|
12
|
6
|
6
|
1
|
1
|
3
|
3
|
1
|
|
41–50 (N = 17)
|
12
|
8
|
5
|
5
|
3
|
0
|
2
|
0
|
1
|
1
|
1
|
|
51–60 (N = 13)
|
13
|
6
|
5
|
6
|
3
|
2
|
1
|
6
|
1
|
0
|
3
|
|
> 60 (N = 20)
|
18
|
14
|
10
|
1
|
3
|
1
|
2
|
2
|
2
|
0
|
0
|
|
Significance
|
P = 0.113
|
P = 0.439
|
P = 0.400
|
P = 0.021
|
P = 0.956
|
P = 0.169
|
P = 0.600
|
P = 0.0004
|
P = 1.000
|
P = 0.467
|
P = 0.053
|
|
Clinical Outcome
| | | | | | | | | | | |
|
Alive (N= 39)
|
30
|
18
|
19
|
8
|
7
|
3
|
5
|
4
|
2
|
0
|
0
|
|
DOC (N= 43)
|
41
|
27
|
18
|
16
|
8
|
6
|
1
|
5
|
5
|
4
|
5
|
|
Significance
|
0.015
|
P = 0.131
|
P = 0.533
|
P = 0.097
|
P = 0.939
|
P = 0.487
|
P = 0.097
|
P = 1.000
|
P = 0.436
|
P = 0.118
|
P = 0.056
|
|
Treatment response¶
| | | | | | | | | | | |
|
CR (N= 21)
|
19
|
11
|
15
|
3
|
4
|
1
|
2
|
3
|
2
|
0
|
0
|
|
DOC/PR (N = 26)
|
24
|
15
|
10
|
12
|
4
|
3
|
1
|
4
|
3
|
2
|
2
|
|
Significance
|
1.000
|
0.716
|
0.024
|
0.020
|
1.000
|
0.617
|
0.579
|
1.000
|
1.000
|
0.495
|
0.495
|
|
HPV type
| | | | | | | | | | | |
|
HPV 16 (N = 47)
|
42
|
27
|
24
|
15
|
9
|
6
|
4
|
5
|
3
|
3
|
2
|
|
HPV 18 (N = 6)
|
5
|
2
|
1
|
1
|
2
|
0
|
1
|
1
|
1
|
0
|
1
|
|
Multiple (N = 11)
|
8
|
7
|
3
|
2
|
1
|
0
|
0
|
2
|
2
|
0
|
1
|
|
Others (N = 16)
|
12
|
9
|
8
|
5
|
2
|
3
|
0
|
0
|
1
|
1
|
1
|
|
significance
|
P = 0.543
|
P = 0.740
|
P = 0.280
|
P = 0.792
|
P = 0.560
|
P = 0.467
|
P = 0.365
|
P = 0.288
|
P = 0.327
|
P = 1.000
|
P = 0.412
|
|
MSI
| | | | | | | | | | | |
|
MSS (N = 30)
|
26
|
20
|
17
|
4
|
2
|
3
|
1
|
2
|
5
|
4
|
2
|
|
MSI-L (N = 9)
|
9
|
6
|
4
|
2
|
1
|
2
|
1
|
0
|
1
|
0
|
2
|
|
MSI-H (N = 9)
|
8
|
2
|
3
|
3
|
4
|
0
|
1
|
3
|
1
|
0
|
1
|
|
Significance
|
P = 0.516
|
P = 0.065
|
P = 0.513
|
P = 0.434
|
P = 0.023
|
P = 1.000
|
P = 0.313
|
P = 0.079
|
P = 1.000
|
P = 0.443
|
P = 0.266
|
- P value corresponds to the P value from the Fisher's Exact test for the first two rows and for the P value from the Analysis of Variance for the last 3 rows. ¶Only patients with at least 5 months follow-up and treatment were considered and patients with treatment unknown or no treatment were excluded. SCC, squamous cell carcinoma; AC, adenocarcinoma; MSS, microsatellite stable; MSI-L, microsatellite instability low; MSI-H, microsatellite instability high; DOC, died of cancer; PR, partial response
